Tumor-bearing Mice
Tumor-bearing Mice - Related Videos
03:59
In Vivo Antitumor Efficacy Analysis of PDT: A Technique to Determine the Phototoxic Potential of a Photosensitizer in Tumor Bearing Mice
0 Views •
2023
Photodynamic therapy (PDT) is a non-invasive and non-surgical method for lung cancer treatment. Photosensitizers selectively accumulate in tumor tissue and lead to tumor cell death in the presence of oxygen and the proper wavelength of light. This video describes the in vivo anti-tumor efficacy analysis using photosensitizer containing nanoparticles in a tumor-bearing mouse, to determine the phototoxic potential of the photosensitizer.
04:21
Isolation of Cytotoxic Neutrophils from Tumor-Bearing Mouse Blood
0 Views •
2025
In this video, we demonstrate the isolation of cytotoxic high-density neutrophils and low-density neutrophils from the blood of a tumor-bearing mouse by discontinuous sucrose gradient centrifugation.
08:55
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
0 Views •
Cited by 111 •
2016
Mice bearing the Colon-26 (C26) carcinoma represent a classical model of cancer cachexia. Progressive muscle wasting occurs in association with tumor growth, over-expression of muscle-specific ubiquitin ligases, and reductions in muscle cross-sectional area. Fat loss is also observed. Cachexia is studied in a time-dependent manner with increasing severity of wasting.
08:19
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
0 Views •
Cited by 5 •
2019
Here, we show therapeutic potential of anti-angiogenic tumor-associated neutrophils after their transfer into tumor-bearing mice. This protocol can be used to manipulate neutrophil activity ex vivo and to subsequently evaluate their functionality in vivo in developing tumors. It is an appropriate model for studying potential neutrophil-based immunotherapies.
14:15
Preparation of Myeloid Derived Suppressor Cells (MDSC) from Naive and Pancreatic Tumor-bearing Mice using Flow Cytometry and Automated Magnetic Activated Cell Sorting (AutoMACS)
0 Views •
Cited by 9 •
2012
This is a rapid and comprehensive method of immunophenotyping Myeloid Derived Suppressor Cells (MDSC) and enriching Gr-1+ leukocytes from mouse spleens. This method uses flow cytometry and AutoMACS Cell Sorting to enrich for viable Gr-1+ leukocytes prior to FACS sorting of MDSC for use in vivo and in vitro assays.
FAQs
Immune status changes which cancer-host interactions the model can represent. Xenograft models commonly use immunodeficient mice, allowing implanted tumors to be studied without a fully intact immune response, whereas syngeneic models preserve immune compatibility. This distinction is important when interpreting tumor growth or treatment responses, because findings may reflect either tumor-intrinsic behavior or interactions involving the host immune system.
Xenograft models commonly involve tumors studied in immunodeficient mice, while syngeneic models maintain compatibility between the tumor and the host immune system. The choice determines which biological relationships remain available for investigation. Xenografts can support studies requiring a compromised immune setting, whereas syngeneic systems are useful when preserving immune compatibility is important to the cancer research question.
Tumor behavior is influenced by more than the cancer cells themselves. In a living host, tumors interact with surrounding tissue and blood vessels, creating conditions that can affect growth and treatment response. Including these relationships helps researchers examine cancer biology in an organismal setting rather than relying only on isolated molecular findings, which may not capture whole-host effects.
Model selection should match the biological feature being investigated and the human disease characteristics the study aims to represent. Researchers may consider whether immune compatibility, tumor growth, metastasis, drug efficacy, toxicity, or treatment resistance is central to the project. Aligning the model with the intended disease feature improves the relevance of conclusions drawn from preclinical cancer research.
These systems support investigation of tumor growth, metastasis, drug efficacy, toxicity, and treatment resistance. Because the tumor develops within a living host, researchers can connect molecular observations with responses occurring across the organism. The resulting data help evaluate how cancer biology and therapeutic effects appear in an in vivo context, complementing findings from more limited experimental systems.
Researchers use them to examine whether a treatment affects tumor growth and to assess drug efficacy and toxicity within a living host. The models can also reveal treatment resistance, providing information beyond an initial response. Their value lies in connecting therapeutic effects with the surrounding tissue, blood vessels, and immune conditions represented by the selected model.
Molecular studies can identify mechanisms or candidate treatments, but they may not show how those findings behave throughout an organism. Tumor-bearing systems provide a setting in which cancer cells interact with host tissues and, depending on the model, an intact or compromised immune system. This helps researchers connect molecular results with broader preclinical responses relevant to cancer research.
They allow researchers to examine metastasis and treatment resistance in the context of a living host, alongside tumor growth and therapeutic response. These outcomes are studied within relationships among cancer cells, surrounding tissues, blood vessels, and immune conditions that vary by model. Consequently, the selected system can help determine whether a finding extends beyond a tumor's immediate molecular behavior.